Dynavax Technologies Corporation

NasdaqGS:DVAX Rapport sur les actions

Capitalisation boursière : US$1.5b

Dynavax Technologies Résultats passés

Passé contrôle des critères 2/6

Dynavax Technologies has been growing earnings at an average annual rate of 53.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 35.3% per year. Dynavax Technologies's return on equity is 2.7%, and it has net margins of 6.9%.

Informations clés

53.7%

Taux de croissance des bénéfices

60.2%

Taux de croissance du BPA

Biotechs Croissance de l'industrie17.0%
Taux de croissance des recettes35.3%
Rendement des fonds propres2.7%
Marge nette6.9%
Prochaine mise à jour des résultats07 Nov 2024

Mises à jour récentes des performances passées

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Recent updates

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: Slow And Steady Wins The Race

Sep 05

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Aug 23

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Ventilation des recettes et des dépenses

Comment Dynavax Technologies gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NasdaqGS:DVAX Recettes, dépenses et bénéfices (USD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 24250171630
31 Mar 2423691590
31 Dec 23232-61600
30 Sep 23361611500
30 Jun 234591111430
31 Mar 236562361430
31 Dec 227232931260
30 Sep 227333201240
30 Jun 226742281190
31 Mar 224701041040
31 Dec 2143972920
30 Sep 21258-39810
30 Jun 21163-6760
31 Mar 21113-62730
31 Dec 2040-75720
30 Sep 2038-97740
30 Jun 2035-138720
31 Mar 2040-129730
31 Dec 1935-156720
30 Sep 1930-159700
30 Jun 1921-163680
31 Mar 1914-160640
31 Dec 188-159650
30 Sep 183-146580
30 Jun 181-128480
31 Mar 180-109400
31 Dec 170-95270
30 Sep 178-89260
30 Jun 178-102320
31 Mar 1710-111360
31 Dec 1611-112370
30 Sep 164-118360
30 Jun 165-113300
31 Mar 164-108250
31 Dec 154-107220
30 Sep 156-102210
30 Jun 157-102190
31 Mar 158-103180
31 Dec 1411-91180
30 Sep 1412-90240
30 Jun 1412-76240
31 Mar 1413-68220
31 Dec 1311-75270

Des revenus de qualité: DVAX has high quality earnings.

Augmentation de la marge bénéficiaire: DVAX's current net profit margins (6.9%) are lower than last year (24.1%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: DVAX has become profitable over the past 5 years, growing earnings by 53.7% per year.

Accélération de la croissance: DVAX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Bénéfices par rapport au secteur d'activité: DVAX had negative earnings growth (-84.5%) over the past year, making it difficult to compare to the Biotechs industry average (-2.3%).


Rendement des fonds propres

ROE élevé: DVAX's Return on Equity (2.7%) is considered low.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé